RRC ID 65869
Author Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.
Title Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Journal Mol Cancer Ther
Abstract Lung cancers harboring common EGFR mutations respond to EGFR tyrosine kinase inhibitors (TKI). We previously reported that tumors with exon 18 mutations are particularly sensitive to irreversible second-generation (2G) afatinib compared with first-generation TKIs (1G-TKI). However, data on the mechanisms of acquired resistance to afatinib are limited. We established afatinib-resistant cells by transfecting Ba/F3 cells with common or exon 18 (G719A and Del18) mutations and subjecting them to chronic exposure to increasing concentrations of afatinib. Afatinib-resistant clones were separately established through N-ethyl-N-nitrosourea (ENU) mutagenesis and exposure to fixed concentrations of afatinib. Rebiopsy samples from patients whose tumors acquired resistance to afatinib were analyzed. Afatinib-resistant cells with Del19, L858R, or G719A developed T790M, whereas those with Del18 acquired novel L792F mutation. ENU mutagenesis screening established 84 afatinib-resistant clones. All Del19 clones and most of the other clones acquired only T790M. However, C797S occurred in subsets of L858R, G719A, and Del18 clones. In addition, subsets of Del18 clones acquired L792F. C797S-acquired cells were sensitive to 1G erlotinib. L792F demonstrated intermediate resistance between T790M and C797S to both 1G- and 3G-TKIs, whereas L792F was the least resistant to 2G-TKIs, particularly dacomitinib. Chronic exposure of Del18 + L792F cells to dacomitinib induced additional T790M. T790M was detected in one of four clinical samples. In conclusion, L792F and C797S, in addition to the major T790M, can develop in afatinib-resistant cells particularly using a low dose of afatinib, and these minor mutations appear to exhibit sensitivity to dacomitinib and erlotinib, respectively. These secondary mutations should be tested in clinical practice. Mol Cancer Ther; 16(2); 357-64. ©2016 AACRSee related article by Talbert et al., p. 344.
Volume 16(2)
Pages 357-364
Published 2017-2-1
DOI 10.1158/1535-7163.MCT-16-0407
PII 1535-7163.MCT-16-0407
PMID 27913578
MeSH Afatinib Alleles Amino Acid Substitution* Animals Antineoplastic Agents / chemistry Antineoplastic Agents / pharmacology* Binding Sites Cell Line, Tumor Codon* Drug Resistance, Neoplasm / genetics* ErbB Receptors / chemistry ErbB Receptors / genetics* Humans Lung Neoplasms / drug therapy Lung Neoplasms / genetics* Mice Models, Molecular Molecular Conformation Mutagenesis Mutation* Protein Binding Protein Kinase Inhibitors / chemistry Protein Kinase Inhibitors / pharmacology Quinazolines / chemistry Quinazolines / pharmacology* Quinazolinones / pharmacology Structure-Activity Relationship
IF 5.615
Human and Animal Cells Ba/F3